KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Deffered Revenue: 2009-2025

Historic Non-Current Deffered Revenue for Regeneron Pharmaceuticals (REGN) over the last 15 years, with Sep 2025 value amounting to $219.2 million.

  • Regeneron Pharmaceuticals' Non-Current Deffered Revenue rose 5.69% to $219.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.2 million, marking a year-over-year increase of 5.69%. This contributed to the annual value of $185.7 million for FY2024, which is 46.57% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Non-Current Deffered Revenue of $219.2 million as of Q3 2025, which was up 6.25% from $206.3 million recorded in Q2 2025.
  • Regeneron Pharmaceuticals' 5-year Non-Current Deffered Revenue high stood at $219.2 million for Q3 2025, and its period low was $27.0 million during Q1 2021.
  • Its 3-year average for Non-Current Deffered Revenue is $170.5 million, with a median of $185.8 million in 2024.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Non-Current Deffered Revenue crashed by 59.03% in 2021, and later surged by 155.22% in 2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Non-Current Deffered Revenue (Quarterly) stood at $73.3 million in 2021, then declined by 4.77% to $69.8 million in 2022, then spiked by 81.52% to $126.7 million in 2023, then surged by 46.57% to $185.7 million in 2024, then grew by 5.69% to $219.2 million in 2025.
  • Its last three reported values are $219.2 million in Q3 2025, $206.3 million for Q2 2025, and $211.8 million during Q1 2025.